Suppr超能文献

铂类化疗药物在晚期非卵巢实体瘤中的“再挑战”。

Platinum-Based Chemotherapy 'Rechallenge' in Advanced Non-ovarian Solid Malignancies.

机构信息

Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK.

Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK.

出版信息

Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e329-e344. doi: 10.1016/j.clon.2022.02.015. Epub 2022 Mar 11.

Abstract

Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.

摘要

铂类化疗是许多实体瘤治疗的基础。然而,晚期疾病患者不可避免地会产生耐药性。铂类药物再挑战在卵巢癌、小细胞肺癌和生殖细胞瘤的治疗管理中是一个成熟的概念。在其他实体恶性肿瘤中,缺乏支持铂类药物再挑战的高质量证据,但这是一种广泛采用的策略。通常,患者处于生命的最后一年,因此疗效、治疗相关毒性和生活质量是治疗建议的关键因素。在这篇综述中,我们评估了铂类药物再挑战的现有证据,并探讨了试图使肿瘤对铂类化疗重新敏感的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验